Endocrinology, Vol 136, 4796-4803, Copyright © 1995 by Endocrine Society

ARTICLES

Dexamethasone-induced antagonism of growth hormone (GH) action by down- regulation of GH binding in 3T3-F442A fibroblasts

AP King and C Carter-Su
Department of Physiology, University of Michigan Medical School, Ann Arbor 48109-0622, USA.

Supraphysiological levels of glucocorticoids, whether endogenous (Cushing's syndrome) or exogenous (glucocorticoid therapy), inhibit growth in children and immature animals. This effect has long been suspected to be due to glucocorticoid antagonism of GH action at the level of peripheral tissues. In the present study we demonstrate direct antagonism of GH action at the cellular level by the artificial glucocorticoid dexamethasone. Dexamethasone was found to inhibit the ability of GH to elicit several early events in GH signaling in 3T3- F442A fibroblasts. Dexamethasone (100 nM) for 24 h decreases by 50-75% GH-induced tyrosyl phosphorylation of mitogen-activated protein kinases ERK1 and ERK2, the transcription factor Stat3/APRF, the GH receptor- associated tyrosine kinase JAK2, and the GH receptor. These effects appear to be specific to GH. Dexamethasone does not inhibit induction of tyrosyl phosphorylation of ERK proteins by epidermal growth factor or phorbol myristate acetate, nor does it block induction of tyrosyl phosphorylation of Stat3/APRF by leukemia inhibitory factor or interleukin-6, or induction of JAK2 by leukemia inhibitory factor or interferon-gamma. Dexamethasone does not decrease the expression of ERK1 or -2, Stat3, or JAK2 proteins. Rather, the effects of dexamethasone on GH action appear to be due to a decrease in the number of GH receptors in the plasma membrane. Twenty-four-hour treatment with dexamethasone leads to a 50% decrease i GH binding, which Scatchard analysis suggests is due to a decrease in GH receptor number. These findings suggest that glucocorticoids antagonize cellular GH action by decreasing GH binding, suggesting a mechanism by which systemic glucocorticoids could antagonize GH action in peripheral tissues.

This article has been cited by other articles:

				L. Deng, K. He, X. Wang, N. Yang, C. Thangavel, J. Jiang, S. Y. Fuchs, and S. J. Frank Determinants of Growth Hormone Receptor Down-Regulation Mol. Endocrinol., July 1, 2007; 21(7): 1537 - 1551. [Abstract] [Full Text] [PDF]

				C. Thangavel, W. Dworakowski, and B. H. Shapiro INDUCIBILITY OF MALE-SPECIFIC ISOFORMS OF CYTOCHROME P450 BY SEX-DEPENDENT GROWTH HORMONE PROFILES IN HEPATOCYTE CULTURES FROM MALE BUT NOT FEMALE RATS Drug Metab. Dispos., March 1, 2006; 34(3): 410 - 419. [Abstract] [Full Text] [PDF]

				K. He, K. Loesch, J. W. Cowan, X. Li, L. Deng, X. Wang, J. Jiang, and S. J. Frank Janus Kinase 2 Enhances the Stability of the Mature Growth Hormone Receptor Endocrinology, November 1, 2005; 146(11): 4755 - 4765. [Abstract] [Full Text] [PDF]

				P. van Kerkhof, M. Smeets, and G. J. Strous The Ubiquitin-Proteasome Pathway Regulates the Availability of the GH Receptor Endocrinology, April 1, 2002; 143(4): 1243 - 1252. [Abstract] [Full Text] [PDF]

				V. Beauloye, B. Willems, V. de Coninck, S. J. Frank, M. Edery, and J.-P. Thissen Impairment of Liver GH Receptor Signaling by Fasting Endocrinology, March 1, 2002; 143(3): 792 - 800. [Abstract] [Full Text] [PDF]

				T. Amit, M. B. H. Youdim, and Z.'e. Hochberg Does Serum Growth Hormone (GH) Binding Protein Reflect Human GH Receptor Function? J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 927 - 932. [Abstract] [Full Text]

				P. Tollet-Egnell, A. Flores-Morales, A. Stavréus-Evers, L. Sahlin, and G. Norstedt Growth Hormone Regulation of SOCS-2, SOCS-3, and CIS Messenger Ribonucleic Acid Expression in the Rat Endocrinology, August 1, 1999; 140(8): 3693 - 3704. [Abstract] [Full Text]

				D. Fernandes, E. Guida, V. Koutsoubos, T. Harris, P. Vadiveloo, J. W. Wilson, and A. G. Stewart Glucocorticoids Inhibit Proliferation, Cyclin D1 Expression, and Retinoblastoma Protein Phosphorylation, but Not Activity of the Extracellular-Regulated Kinases in Human Cultured Airway Smooth Muscle Am. J. Respir. Cell Mol. Biol., July 1, 1999; 21(1): 77 - 88. [Abstract] [Full Text]

				D. Defalque, N. Brandt, J.-M. Ketelslegers, and J.-P. Thissen GH insensitivity induced by endotoxin injection is associated with decreased liver GH receptors Am J Physiol Endocrinol Metab, March 1, 1999; 276(3): E565 - E572. [Abstract] [Full Text] [PDF]

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]

				D. B. Allen, J. R. Julius, T. J. Breen, and K. M. Attie Treatment of Glucocorticoid-Induced Growth Suppression with Growth Hormone J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2824 - 2829. [Abstract] [Full Text]

				C. Jux, K. Leiber, U. Hugel, W. Blum, C. Ohlsson, G. Klaus, and O. Mehls Dexamethasone Impairs Growth Hormone (GH)-Stimulated Growth by Suppression of Local Insulin-Like Growth Factor (IGF)-I Production and Expression of GH- and IGF-I-Receptor in Cultured Rat Chondrocytes Endocrinology, July 1, 1998; 139(7): 3296 - 3305. [Abstract] [Full Text] [PDF]

				C. A. Gebert, S.-H. Park, and D. J. Waxman Regulation of Signal Transducer and Activator of Transcription (STAT) 5b Activation by the Temporal Pattern of Growth Hormone Stimulation Mol. Endocrinol., April 1, 1997; 11(4): 400 - 414. [Abstract] [Full Text]

				A. P.J. King, M.-J. Tseng, C. D. Logsdon, N. Billestrup, and C. Carter-Su Distinct Cytoplasmic Domains of the Growth Hormone Receptor Are Required for Glucocorticoid- and Phorbol Ester-induced Decreases in Growth Hormone (GH) Binding. THESE DOMAINS ARE DIFFERENT FROM THAT REPORTED FOR GH-INDUCED RECEPTOR INTERNALIZATION J. Biol. Chem., July 26, 1996; 271(30): 18088 - 18094. [Abstract] [Full Text] [PDF]